Interdisciplinary Training Network for Validation of Gram-negative Antibacterial Targets (H2020-MCSA-ITN-2014)

Projekt: Forskningsprojekt


Beskrivning (abstrakt)

Antimicrobial resistance is posing a continuously-rising threat to global health. Indeed, one key recommendation from the recent “Action plan against the rising threats from Antimicrobial Resistance” report (submitted by the Commission to the
European Parliament and Council (15.11.2011)) is the development of effective antimicrobials or alternatives for treatment of human and animal infections. The INTEGRATE project is a direct response to this. We have assembled a team of 10
beneficiaries from eight EU member states, encompassing both academic and non-academic sectors and different disciplines, to form a consortium committed to training Early Stage Researchers (ESRs) in the discovery and preclinical validation of novel Gram-negative antibacterial agents and antibacterial targets. The principle aim of the consortium is to provide a training platform where students are exposed to every aspect of the antimicrobial discovery process, ranging from target identification and validation, through organic synthesis, in silico design and compound screening, to mode-of-action and possible resistance mechanisms. This exposure will be accomplished through a concrete secondment plan, coupled with a series of high-level consortium-wide training events and networking programmes. Our intention is to reverse the current fragmentation of approaches towards antibacterial discovery through mutual cooperation. The INTEGRATE training framework is built on an innovative research project aimed at targeting important but non-essential gene products as an effective means of reducing bacterial fitness, thereby facilitating clearance of the pathogen by the host immune system. To achieve this, the individual work programmes have been designed to seamlessly inter-mesh contributions from the fields of in silico design, organic synthesis, molecular biology and biochemistry, and the very latest in vitro and in vivo screening technologies.
Gällande start-/slutdatum01/01/201531/12/2018


  • European Commission / Horizon 2020: 254 753,39 €


  • 317 Farmaci
  • Vanesa Garrido

    Päivi Tammela (Värd)

    3 apr. 201831 maj 2018

    Aktivitet: Typer för att vara värd för en besökareAkademiskt besök på HU

  • Alyssa McVey

    Päivi Tammela (Värd)

    5 feb. 201829 mars 2018

    Aktivitet: Typer för att vara värd för en besökareAkademiskt besök på HU


    Viviana Gatta (Besökande forskare)

    26 feb. 201823 mars 2018

    Aktivitet: Typer för besök till extern institutionAkademisk besök på annan institution